Traders Purchase High Volume of Cardiff Oncology Put Options (NASDAQ:CRDF)

Cardiff Oncology, Inc. (NASDAQ:CRDF) was the target of some unusual options trading activity on Tuesday. Stock traders acquired 4,095 put options on the company. This represents an increase of 348% compared to the average volume of 914 put options.

Analyst Upgrades and Downgrades

Several research firms recently commented on CRDF. Craig Hallum assumed coverage on shares of Cardiff Oncology in a research note on Friday, September 6th. They set a “buy” rating and a $8.00 price objective for the company. HC Wainwright cut their price target on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, November 8th.

Institutional Trading of Cardiff Oncology

A number of institutional investors have recently bought and sold shares of CRDF. Point72 DIFC Ltd purchased a new position in shares of Cardiff Oncology in the second quarter worth $27,000. Ground Swell Capital LLC purchased a new position in Cardiff Oncology in the 2nd quarter worth $38,000. Dimensional Fund Advisors LP lifted its position in Cardiff Oncology by 34.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock worth $42,000 after acquiring an additional 4,892 shares during the period. SG Americas Securities LLC purchased a new stake in Cardiff Oncology during the 3rd quarter valued at about $64,000. Finally, Invst LLC acquired a new position in shares of Cardiff Oncology in the second quarter valued at about $74,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Stock Performance

Shares of NASDAQ CRDF opened at $3.78 on Wednesday. Cardiff Oncology has a fifty-two week low of $1.25 and a fifty-two week high of $6.42. The company has a market cap of $193.27 million, a PE ratio of -3.88 and a beta of 1.89. The business has a 50-day simple moving average of $2.80 and a two-hundred day simple moving average of $2.60.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.